Category: drug design

Work by group at Australian university faces scrutiny

A journal is investigating research by a group in Australia, after receiving “serious allegations” regarding a 2017 paper about treating eye burns.

The journal, Frontiers in Pharmacology, has issued an expression of concern (EOC) for the 2017 paper while it investigates. The notice does not specify the nature of the allegations.  Meanwhile, several other papers by the three researchers, based at Deakin University in Geelong, Australia, have also come under scrutiny. Late last month, Frontiers in Pharmacology retracted a 2015 paper by Kislay Roy, Rupinder Kanwar, and Jagat R Kanwar, citing image duplication. A 2015 paper in Biomaterials received a correction in May 2017, again flagging image duplication.

Roy, the first author on the papers, is a postdoctoral research fellow; Rupinder Kanwar, a middle author, is a senior lecturer; and Jagat R Kanwar, the corresponding author on all three, is head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research.

Gearóid Ó Faoleán, the ethics and integrity manager at Frontiers in Pharmacology, explained that the investigation into the flagged article is ongoing and the EOC “must serve as the extent of our public statement for the present.”

A spokesperson for Deakin University declined to comment on the allegations: Continue reading Work by group at Australian university faces scrutiny

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease. 

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate

NIH researcher doctored 11 figures in 2016 paper, says ORI

A former Research Training Awardee at the National Institutes of Health “falsified and/or fabricated data” in 11 figures in a 2016 paper, according to the U.S. Office of Research Integrity.

This is the first finding of misconduct issued this year by the ORI.

According to the finding, published in the Federal Register, Brandi M. Baughman — formerly at the National Institute of Environmental and Health Sciences (NIEHS) — tweaked data and text in a PLOS ONE paper about screening for compounds that inhibit an enzyme known as inositol phosphate kinase. According to the notice, however, some of those experiments didn’t proceed as described:

Continue reading NIH researcher doctored 11 figures in 2016 paper, says ORI

Author duplicated a figure in three papers; two get retracted

Two journals have retracted two papers by the same group within months of each other, after editors were independently tipped off that they contained duplicated figures representing different experiments.

The two papers were published by PLOS ONE and The Egyptian Journal of Biochemistry and Molecular Biology (EJBMB) in 2015 and 2014, respectively. According to the PLOS ONE paper’s corresponding author, last author Saad A. Noeman from Tanta University in Egypt used the same Figure 1 in both papers, along with another 2013 paper in EJBMB.

Corresponding author Yasser S. El-Sayed, head of the Department of Forensic Medicine and Toxicology at Damanhour University in Egypt, told us he learned of this issue after a reader brought the figure manipulation and duplication concerns to PLOS ONE’s attention.

El-Sayed said that he tried to figure out what had happened.

Continue reading Author duplicated a figure in three papers; two get retracted

Negligence by stressed-out postdoc led to retraction of high-profile paper, supervisor says

The timing was tight, but Sergio Gonzalez had done it. Gonzalez, a postdoctoral researcher at the Institute for Neurosciences of Montpellier (INSERM) in France, had a paper accepted in a top journal by the end of 2015, just in time to apply for a small number of highly sought-after permanent research positions that open up in France each year.

If Gonzalez had missed the January deadline for this system of advancement, known as concours, he would have had to wait until the following cycle to apply.

Once his paper was accepted by the Journal of Clinical Investigation, Gonzalez could breathe a sigh of relief. He began being invited to interviews. But then, a comment showed up at PubPeer.

Continue reading Negligence by stressed-out postdoc led to retraction of high-profile paper, supervisor says

3rd retraction appears for fired Pfizer breast cancer researcher

Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.

The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.

As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.

According to the notice, Yin and five of her co-authors agreed to the retraction:

Continue reading 3rd retraction appears for fired Pfizer breast cancer researcher

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Breast cancer studies by fired Pfizer employee retracted

Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.

One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.

Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted

Authors retract tanning-UV radiation study for lacking approval

Researchers have agreed to pull a 2015 study exploring whether a plant extract can safeguard tanners from ultraviolet exposure after not obtaining formal approval from an ethics committee.

According to the first author, the problem lay in a misunderstanding – when they originally applied for approval six years ago, the researchers believed they didn’t need to go through a formal approval process, since the compound was commercially available without a prescription. Once they realized their mistake, they chose to retract the paper.

Here’s the retraction note for “Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study,” published in Photodermatology Photoimmunology & Photomedicine.  Continue reading Authors retract tanning-UV radiation study for lacking approval

Japan group earns 4th retraction following investigation

Researchers in Japan have issued their fourth retraction, noting that the same figures were used to depict different experimental conditions.

The group lost two papers in 2015 for the same reason, following a misconduct investigation at Oita University in Japan. Last year, the same group notched another retraction, and pegged the responsibility for the problematic figures on first author Satoshi Hagiwara.

Now, the group has published a fourth retraction in the European Journal of Pharmacology; the latest notice doesn’t identify a culprit. All four retracted papers list Hagiwara as first author.

Here’s the latest retraction notice: Continue reading Japan group earns 4th retraction following investigation